A method for treating a disease, disorder or condition in a mammal, wherein the disease, disorder or condition is selected from Sezary Syndrome, Hodgkin's Disease, Non-Hodgkin's Lymphoma, multiple myeloma, hypereosinophilic syndromes, mastocytosis or thrombocythemia and wherein the method comprises administering to the mammal in need thereof an effective amount of a compound of formula (I):
- wherein:
- is selected from:
- n is 1, 2, 3, 4, 5, or 6;
- R1 is —R9a—C(R10)2—R9b—, —R9a—C(O)—R9b—, —R9a—S(O)t—R9b (where t is 0, 1 or 2), —R9a—OR9b—,
- —R9a—C(O)N(R11a)—R9b—, —R9a—N(R11a)C(O)—R9b— or —R9a—N(R11a)—R9b—;
- provided that when A is
- R1 is not —R9a—C(R10)2—R9b—;
- R2 and R3 are each independently selected from hydrogen, alkyl or —R9—OR11, provided that at least one of R2 and R3 is —R9—OR11 when R6 is hydrogen;
- R4a and R4b are each independently selected from hydrogen, alkyl, —R9—OR11 or —C(O)OR11;
- R5 is independently selected from hydrogen, oxo, cyano, nitro, halo, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, —R9—OR11, —R9—C(O)R11, —R9—C(O)OR11, —R9—N(R11)R12, —R9—C(O)N(R11)R12, —R9—N(R11)C(O)R12, —R9—N(R11)—R14—N(R11)R12, —R9—N(R11)C(O)—R9—N(R11)R12, —R9—N(R11)C( O)N(R11)—OR12, —R9—N(R11)C(═NR11)N(R11)R12, —R9—N(R11)S(O)pR11 (where p is 1 or 2), —R9—N(R11)C(S)N(R11)R12 or —R9—N(R11)C(O)—R9—N(R11)S(O)pR12 (where p is p 1 or 2);
- each R6 and R8 is independently selected from hydrogen, alkyl, halo or haloalkyl;
- R7 is hydrogen, alkyl, halo or haloalkyl;
- each R9, R9a and R9b is independently a direct bond or a straight or branched alkylene chain;
- each R10 is independently hydrogen, alkyl, —OR11, —C(O)OR11, —C(O)N(R11)R12, —N(R11)R12 or —N(R11)C(O)R11;
- each R11, R11a and R12 is independently hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl;
- and
- R14 is a straight or branched alkylene chain;
- or a stereoisomer thereof or a pharmaceutically acceptable salt thereof;
- provided that compounds of formula (I) do not include the following compounds:
- (1S,2R,4aS,8aS)-1-(3-methoxy-5-methylphenoxymethyl)-2,5,5,8a-tetramethyl-decahydronaphthalen-2-ol;
- (1S,2R,4aS,8aS)-1-(3,5-dimethoxyphenoxymethyl)-2,5,5,8a-tetramethyl-decahydronaphthalen-2-ol;
- (1S,2R,4aS,8aS)-1[3,5-bis(propan-2-yloxy)phenoxymethyl]-2,5,5,8a-tetramethyl-decahydronaphthalen-2-ol;
- (1R,2R,8aS)-1-((3,5-dimethoxyphenylsulfonyl)methyl)-2,5,5,8a -tetramethyldecahydronaphthalen-2-ol;
- (1R,2R,4aS,8aS)-1-{[(3-methoxy-5-methylphenyl)sulfanyl]methyl}-2,5,5,8a-tetramethyl-decahydronaphthalen-2-ol;
- (1R,2R,4aS,8aS)-1-{[(3-methoxyphenyl)sulfanyl]methyl}-2,5,5,8a-tetramethyl-decahydronaphthalen-2-ol;
- and
- (1R,2R, 4aS,8aS)-1-{[(3,5-dimethoxyphenyl)sulfanyl]methyl}-2,5,5,8a-tetramethyl-decahydronaphthalen-2-ol.